Two small clinical trials (VCU-ART 1 and 2) have shown that 2 weeks daily subcutaneous administration of the IL-1 inhibitor, Anakinra, was safe and suppressed serum CRP levels in the post-MI period, although the effects on preventing adverse LV remodeling were mixed (see Table 1) (Abbate et al., 2010, Abbate et al., 2013). This evidence concerns the gene IL1A and myocardial infarction.